ReviewCurrent opinion in infectious diseases2026
Alveolar echinococcosis.
Review in Current opinion in infectious diseases, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
purpose of reviewAlveolar echinococcosis is a wildlife zoonotic disease. Clinically and radiologically, it presents in a manner similar to hepatic malignancy. The aim of our review is to summarize the current standard of clinical management of alveolar echinococcosis. We also want to raise awareness and promote an integrated approach for this neglected tropical disease (NTD). RECENT
findingsData suggest increased prevalence of alveolar echinococcosis in some parts of the world. This may be due to intensified surveillance, spread of the disease, decreasing control efforts or a combination of these. Development of new diagnostics and treatment modalities is very slow, constrained by lack of investment into research. SUMMARY: Treatment options for alveolar echinococcosis have not changed in decades. Cure is only available for early and limited hepatic disease amenable to R0-surgical resection. Advanced disease, ineligible for surgery, is treated with benzimidazoles with a parasitostatic effect on Echinococcus multilocularis. The prognosis of alveolar echinococcosis ranges from excellent to poor depending mainly on the extent of hepatopathy induced by irreversible damage to the biliary and vascular system of the liver. Benzimidazole intolerance dramatically worsens prognosis, as parasitic growth cannot be suppressed in inoperable patients.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.